Giuliani Mario Germano
CIK: 0001814882
Associated companies
Transaction History
| RPRX | ▲ Buy | Grant | 7,747 | $0 | 6/23/2023 | View on chart |
| RPRX | ▼ Sell | Open Market | 84,302 | $3.6M | 12/5/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 197,766 | $8.7M | 12/2/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 165,000 | $7.3M | 12/1/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 32,593 | $1.3M | 9/28/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 211,380 | $8.7M | 9/22/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 125,697 | $5.2M | 9/21/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 130,330 | $5.3M | 9/20/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 267,815 | $11.0M | 9/20/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 232,185 | $9.6M | 9/19/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 154,986 | $6.5M | 9/16/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 154,154 | $6.5M | 9/15/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 190,860 | $8.1M | 9/14/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 237,619 | $10.2M | 9/8/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 261,881 | $11.2M | 9/7/2022 | View on chart |
| RPRX | ▼ Sell | Open Market | 500 | $22K | 8/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Royalty Pharma Declares Q4 2026 Dividend
Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.
Royalty Pharma Declares Q4 2026 Dividend. Royalty Pharma announced its fourth-quarter 2026 dividend, a routine move that supports its status as a consistent income provider with a yield near 3%. Recent commentary also highlights the company's valuation metrics, noting that its multiples may offer an attractive risk-reward balance for some market participants. The stock currently trades within its 52-week range, with analysts maintaining a consensus target price above current levels.